Your browser doesn't support javascript.
loading
Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinoma.
Yin, Haisen; Que, Risheng; Liu, Chunying; Ji, Weidan; Sun, Bin; Lin, Xuejing; Zhang, Qin; Zhao, Xinying; Peng, Zhangxiao; Zhang, Xiaofeng; Qian, Haihua; Chen, Lei; Yao, Yonggang; Su, Changqing.
Afiliação
  • Yin H; Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai, 200438, China; Department of Gastroenterology, Jingzhou Central Hospital & Clinical Medical College, Yangtze University, Jingzhou, 434023
  • Que R; Department of Surgery, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, Zhejiang, China.
  • Liu C; Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai, 200438, China.
  • Ji W; Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai, 200438, China.
  • Sun B; Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai, 200438, China.
  • Lin X; Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai, 200438, China.
  • Zhang Q; Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai, 200438, China.
  • Zhao X; Department of Gastroenterology, Jingzhou Central Hospital & Clinical Medical College, Yangtze University, Jingzhou, 434023, Hubei Province, China.
  • Peng Z; Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai, 200438, China.
  • Zhang X; Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai, 200438, China.
  • Qian H; Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai, 200438, China.
  • Chen L; Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai, 200438, China.
  • Yao Y; Department of Gastroenterology, Jingzhou Central Hospital & Clinical Medical College, Yangtze University, Jingzhou, 434023, Hubei Province, China.
  • Su C; Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai, 200438, China; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College, Xuzhou, 22
Cancer Lett ; 425: 54-64, 2018 07 01.
Article em En | MEDLINE | ID: mdl-29608986

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Alcaloides / Survivina / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Animals / Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2018 Tipo de documento: Article País de publicação: Irlanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Alcaloides / Survivina / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Animals / Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2018 Tipo de documento: Article País de publicação: Irlanda